PT  - JOURNAL ARTICLE
AU  - Cunningham, Muriel
ED  - Mahlangu, Johnny
TI  - AFFINITY
DP  - 2015 Sep 10
TA  - MD Conference Express
PG  - 9--10
VI  - 15
IP  - 21
4099  - http://mdc.sagepub.com/content/15/21/9.2.short
4100  - http://mdc.sagepub.com/content/15/21/9.2.full
AB  - A pivotal open-label trial of rVIII-SingleChain in adolescents and adults with hemophilia A was conducted. Pharmacokinetic results indicate that, when compared with octocog alfa, this agent has lower clearance, a greater area under the curve, and a longer half-life. rVIII-SingleChain is efficacious and well tolerated when it is used prophylactically or on demand.